Compare ARK Genomic Revolution ETF (ARKG) vs Booz Allen Hamilton Holding Corporation (BAH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Booz Allen Hamilton Holding Corporation — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while Booz Allen Hamilton Holding Corporation trades at $63.6 (market cap $7.53B). The key difference: Booz Allen Hamilton Holding Corporation pays a 3.76% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Booz Allen Hamilton Holding Corporation nearer its low. Which is the better fit depends on your goals.
| ARKG | BAH | |
|---|---|---|
Sector | Sector/Thematic | Industrials |
52-Week High | $43.57 | $115.95 |
52-Week Low | $23.09 | $59.71 |
Market Cap | — | $7.53B |
Enterprise Value | — | $10.92B |
Dividend Yield | — | 3.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Booz Allen Hamilton (BAH) trades at $62.76, down 0.63% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 9.1 and robust profitability, including an 80.17% ROE. Recent earnings have mostly beaten estimates, and the company announced a partnership with OpenAI to advance AI in national security. Cash flow from operations improved to $1.01B in 2025, though net cash flow turned negative in 2026 projections.
BAH presents a compelling value opportunity with solid earnings growth and a consensus price target of $80.80, implying significant upside. Risks include persistent civil segment weakness noted in guidance and rising debt-to-asset ratios. Investor sentiment is mixed, with nearly half of analysts rating it a buy, but technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
Read more on BAH →
